Refocus Group Readies for Commercialization of VisAbility™ Micro Insert System; Expands Salesforce and Manufacturing Capacity

DALLAS, April 12, 2018 -- Refocus Group, a pioneer in vision-correcting technology, announced today that it has expanded its manufacturing and assembly capacity, and is strategically strengthening its administrative, marketing and sales teams, in preparation for possible FDA approval of its VisAbility™ Micro Insert System for presbyopia. The company has leased a new 8,200 sq. ft. facility in Irving, Texas. An expanded marketing and sales team will be in place by the second quarter of 2018.

The VisAbility™ Micro Insert System is the first and only presbyopic procedure performed outside the eye’s line-of-sight, developed to restore near vision without any compromise to distance vision or depth perception, a potential drawback of other presbyopic treatments. The VisAbility™ procedure is performed in the sclera (white of the eye), so it does not alter the cornea or natural lens, preserving the eye for future refractive or cataract procedures. 

Physicians will have the opportunity to learn more about the company and the surgical approach of the VisAbility™ Micro Insert System at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS), April 13-17, 2018 in Washington, DC. An instructional course, “Managing Presbyopia with Scleral Micro Insert Surgery,” will be presented by Barrie D. Soloway, MD on Monday, April 16, from 1-2:30 p.m. in Room 145A of the Convention Center. In addition, five clinical investigators also will present papers at the conference, sharing a sub-sample outcome analysis of the VisAbility™ Micro Insert System.

Nearly 90 million Americans, and 1.7 billion people worldwide, are affected by presbyopia, which causes the inevitable loss of near vision after age 40, making it difficult to read, do hobby work or use a cell phone, without the aid of reading glasses. 

“We have reached every milestone to date, and are excited to be ramping up for commercialization,” said Mike Judy, CEO of Refocus Group. “We look forward to entering the market as the newest and most promising treatment for presbyopia.” Judy is scheduled to present an update on the VisAbility™ Micro Insert System during the Ophthalmology Innovation Summit at ASCRS, on April 12, 2018.

The VisAbility™ procedure is performed on both eyes and consists of inserting four, micro-thin inserts, smaller than a grain of rice, just below the surface of the sclera. The inserts are so small they can’t be felt, and are unnoticeable to others in normal gaze. The outpatient procedure is performed with topical (eye drop) anesthesia.

About Refocus Group Inc.
Refocus Group Inc. is a pioneer in vision-correcting technology and is the developer of the VisAbility™ Micro Insert System, an investigational medical device currently undergoing clinical trials in the United States, which may be able to restore the natural ability to focus on objects up close and eliminate the need for reading glasses. The company is headquartered in Dallas.

www.refocus-group.com

Media Contact
Capwell Communications
[email protected]
949-999-3303